Evotec OAI achieves first milestone in partnership with Boehringer Ingelheim

Less than a year after the start of the three-year research collaboration between Boehringer Ingelheim and Evotec OAI on selected G-Protein Coupled Receptors (GPCRs) the first project milestone has been successfully achieved.

Under the terms of the drug discovery collaboration, Evotec OAI has received a first research milestone payment from Boehringer Ingelheim.

The payment was granted for the identification of a number of lead series for a priority target of this collaboration. Further projects within the multi-target collaboration are progressing on schedule. Evotec OAI is entitled to additional payments from Boehringer Ingelheim based on the achievement of further milestones. Further financial details of the payment were not disclosed.

'We are very pleased with the progress achieved in the collaboration on GPCR targets, which constitute one of the most proven drug target classes in the medical area. Generation of novel leads against a disease relevant GPCR target was successfully achieved in a short time period,' said Professor Mikael Dolsten, head of corporate division pharma research/discovery, Boehringer Ingelheim.

'The basis for this first milestone achievement was both the excellent drug discovery performance and the good collaboration spirit between the Boehringer Ingelheim and Evotec scientists. We anticipate valuable results from this collaboration.'